Global study debunks ‘lab leak' theory, finds Covid-19 virus didn't originate in Wuhan
A landmark international study has offered compelling evidence that the coronavirus that caused the Covid-19 pandemic did not originate in Wuhan, China, challenging US President Donald Trump's
laboratory leak theory
Advertisement
The study, published in the peer-reviewed journal Cell on May 7, was led by the University of Edinburgh and involved researchers from 20 institutions across the US, Europe, and Asia, including China.
The team analysed 167 bat coronavirus genomes and traced the origins of the virus that causes Covid-19 to bat populations in northern Laos and southwest China's Yunnan province, where its most recent ancestor circulated five to seven years before the pandemic emerged.
The findings counter assertions by the White House, which claimed on a revamped
government website in April that a Chinese lab leak was the 'real source' of the Covid-19 pandemic. The website continues to display the headings 'LAB LEAK', 'TRUTH', and 'ORIGIN' in bold capital letters.
Specifically, the researchers looked at the genomes of sarbecoviruses – coronaviruses that can cause severe respiratory illness. They include Sars-CoV-1, which was responsible for the 2002–2004 severe acute respiratory syndrome (Sars) outbreak, and Sars-CoV-2, which caused the
Covid-19 pandemic
Advertisement
Lead author Jonathan Pekar said the study showed that the original Sars-CoV-1 was circulating in western China just a year or two before Sars emerged in the southern province of Guangdong in late 2002.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
43 minutes ago
- South China Morning Post
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk's semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting. Novo Nordisk's patent will expire in 2031 in Japan and Europe and 2032 in the US, according to its latest annual report. 'The landscape in China is expected to become even more competitive than in developed markets, where the GLP-1 category is primarily dominated by leading multinational pharmaceutical companies,' said Helen Chen, L.E.K.'s global healthcare and life sciences co-head, in a report on May 15. GLP-1 drugs mimic natural hormones, which signal the pancreas to release more insulin when blood-sugar levels are high, and also support weight loss by slowing digestion and reducing appetite. 04:12 One reporter's weight-loss journey and what a 'healthy body' means to him One reporter's weight-loss journey and what a 'healthy body' means to him Driven by sales growth of semaglutide, Novo Nordisk became the 10th largest drug company in the world in terms of revenue. London-based consultancy Evaluate said the firm's revenue rose 25 per cent to US$42.1 billion last year.
South China Morning Post
an hour ago
- South China Morning Post
China boosts research of Southeast Asian populations overlooked in Human Genome Project
For more than two decades, the Human Genome Project (HGP) – a landmark scientific endeavour led by Western nations – mapped humanity's genetic blueprint, yet the rich diversity of Southeast Asia was overlooked. Despite being home to nearly 300 million people, including the world's largest indigenous population, mainland Southeast Asia (MSEA) contributed a mere 1.57 per cent to global genomic databases, with most data derived from diaspora communities rather than local populations. Chinese researchers say they now aim to rectify the omission. Scientists from the Kunming Institute of Zoology, an affiliate of the Chinese Academy of Sciences, have spearheaded a decade-long collaboration with 34 Southeast Asian research teams, culminating in the first comprehensive genomic atlas of the region – the SEA3K data set – which was published in Nature on May 14. 02:43 Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA The study revealed striking insights, including that MSEA populations harbour unique genetic adaptations to tropical challenges as well as distinct Denisovan ancestry linked to Russia's far east. Before China took a role in the research, fewer than 200 indigenous genomes from MSEA existed in global databases, with neighbouring India contributing most via Southeast Asian diaspora samples, according to the paper. Even city state Singapore, a regional sequencing hub, accounted for 92 per cent of the region's limited data, leaving Cambodia, Laos, Myanmar, Thailand and Vietnam virtually invisible in the genomic era. 'For over a decade, we conducted fieldwork in Southeast Asian rainforests, adhering to local ethical protocols, fostering community engagement and documenting indigenous cultural and linguistic contexts,' corresponding author Su Bing said in an interview with China Science Daily on May 19. Researchers collected samples from Southeast Asian populations covering six countries, five prominent language families and 30 ethnic languages. They completed genome sequencing for 3,023 cases, including 40 high-accuracy long-read sequencing data.
South China Morning Post
an hour ago
- South China Morning Post
Chinese biotech firm Akeso tumbles on US partner Summit's setback for cancer drug
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Advertisement Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics' Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9. Summit said on Friday that the US Food and Drug Administration (FDA) indicated that a 'statistically significant' benefit on overall survival – from start of treatment to death – was required to support marketing approval for the ivonescimab antibody. Ivonescimab targets non-small cell lung cancer patients whose tumours showed a genetic abnormality that drives unusual cell growth. Akeso is based in Zhongshan in China's southern Guangdong province. Photo: Handout Summit said the first global phase-three clinical trial of Akeso's ivonescimab showed that it was effective in restoring patients' immune systems capabilities to attack tumour cells and slowed tumour progression. But ivonescimab had not yet demonstrated a survival benefit for patients in the study.
